



CONSORTIUM

The RELENT Consortium is a multidisciplinary group of scientists and clinical investigators whose goal is to develop individualised treatment for chronic autoimmune diseases, such as rheumatoid arthritis and vasculitis. The whole group consists of 12 partners from 6 different European countries, and one partner from Australia whose expertise is not available elsewhere in the world.



PROJECT COORDINATOR

Prof. Renate Kain, M.D., Ph.D.
Project Coordinator
Phone +43 1 40400 3681
Fax +43 1 40400 37070
Medical University of Vienna
Spitalgasse 23
1090 Vienna
Austria

 renate.kain@meduniwien.ac.at
 <https://www.meduniwien.ac.at/web>

 info@relent.eu
 <https://www.relent.eu>
 [Relent_EU](#)
 [Relent-project](#)

EUROPEAN PROJECT >RELENT



RELENT: RElapses prevENTion in chronic autoimmune disease: common mechanisms and co-morbidities



Autoimmune Disease

People has an estimated 2.5 million human immunodeficiency virus positive individuals worldwide. This study analyses the determinants of HIV infection to an HIV programme in Nigeria and other developing countries. The methodology and electronic databases of reviewed journals, analysed in terms of prevalence of HIV (2011) determinants of health model. A v... are predominant over other... over 10% of funding... and...



© Pictures: RELENT, jarun011



RELENT has received funding from the European Union's 2020 research and innovation programme under grant agreement No 668036. The views expressed here are the responsibility of the authors only. The EU Commission takes no responsibility for any use made of the information set out.

Monash University has received funding for RELENT from the National Health and Research Council Australia via the European Union Collaborative Research Grant



RELapses prevENTION in chronic autoimmune disease. Understanding common mechanisms and co-morbidities is a multidisciplinary group of nine scientific partners and four SMEs from Europe and Australia funded by the European Union's Horizon 2020 research and innovation programme.

RELENT was launched to address the unmet need for better ways to individualise the treatment of chronic autoimmune and inflammatory diseases thereby reducing the unacceptably high morbidity and mortality they cause.

RELENT's overall mission is to understand common mechanisms of diseases and their relevance in co-morbidities, thereby transforming the clinical outcome for patients with severe autoimmune and inflammatory diseases. Provide the scientific underpinning by closing the knowledge gap in common mechanisms of disease. This should result in a more individualised and thus safer, and more effective, management for severe immune-mediated disease in affected females and males.

RELENT will



Closely collaborate with patient's organisations giving the relevant target groups rapid information about the latest research results & access to participation in clinical studies.



Minimize treatment-associated toxicities, disease-related damage and long-term morbidity and reduce health care costs.



Allow predictive monitoring and individualised treatment minimizing drug toxicities and secondary co-morbidities.



Validate and implement methods to measure disease activity and monitor treatment more accurately thus avoiding drug toxicity and side effects such as infections.

Acronym	RELENT
Start date	01.11.2015
End Date	30.04.2020
Duration	4.5 years
Project Budget	(6.469.522,50
EC Funding	(5.999.431,25
Call	H2020-PHC-2015

The RELENT project will analyse data from a variety of measurements (clinical, serological, genetic transcriptome) and thus develop new biomarkers for these diseases. These should enable the tailoring of the most efficacious treatment to individual patients with chronic autoimmune disease.